VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE

W A Roscoe1, M E Welsh, D E Carter

  • 1Departments of Physiology and Pharmacology, and Diagnostic Imaging, University of Western Ontario, Ontario, Canada.

Journal of Neuroimmunology
|February 24, 2009
PubMed

Insights

In acute experimental autoimmune encephalomyelitis (EAE), inhibiting vascular endothelial growth factor (VEGF) improved clinical outcomes and reduced demyelination. However, this treatment showed no benefit in chronic EAE, suggesting a critical role for VEGF in early disease stages.

Area of Science:

  • Neuroimmunology
  • Vascular Biology
  • Experimental Pathology

Background:

  • Increased vascular endothelial growth factor (VEGF) expression is linked to demyelinated lesions in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE).
  • Vascular changes, particularly those involving VEGF, are implicated in the formation of central nervous system (CNS) plaques.

Purpose of the Study:

  • To investigate vascular alterations in acute and chronic EAE in mice induced with myelin oligodendrocyte glycoprotein (MOG) peptide.
  • To determine the functional role of VEGF in EAE by inhibiting VEGF receptor 2 (VEGFR2) using SU5416 (Semaxinib).

Main Methods:

  • Induction of EAE in C57BL/6 mice using MOG (35-55) peptide.
  • Treatment with SU5416 (VEGFR2 inhibitor) or vehicle during acute or chronic EAE phases.
  • Assessment of clinical scores, spinal cord pathology (demyelination, cellular infiltration, laminin deposits), blood vessel density, and angiogenic gene expression.

Main Results:

  • MOG induction caused demyelination, immune cell infiltration, laminin deposits, and axonal loss.
  • In acute EAE, SU5416 treatment significantly improved clinical scores, reduced demyelination and cellular infiltration, and decreased blood vessel density and laminin abnormalities.
  • VEGF expression positively correlated with clinical scores and pathology in acute EAE.
  • SU5416 treatment during chronic EAE showed no significant improvement in clinical scores or pathology.
  • Microarray analysis revealed increased expression of angiogenic RNA transcripts in acute EAE.

Conclusions:

  • VEGF plays a critical role in the vascular pathology of acute EAE, and its inhibition can ameliorate disease.
  • Vascular alterations, including increased VEGF and laminin deposits, are associated with CNS lesion formation in EAE.
  • Targeting VEGF may be a viable therapeutic strategy for early-stage MS, but not for chronic disease stages.